Back to results
US 2021/0355540 A1Published application
Assessment of risk of aneuploidy
AssigneeBluegnome Limited
InventorAlan Handyside
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to methods and materials for use in detecting abnormalities of the number of whole chromosomes or chromosome regions (aneuploidy). It has particular utility for assessing the risk of aneuploidy of eggs (i.e., oocytes), fertilised eggs or embryos developed therefrom in the context of in vitro fertilisation.
Claims21
(canceled)
A system for assessing centromeric heterozygosity of maternal meiotic origin in a human egg, the human egg comprising a first polar body (PB1), the first polar body comprising one or more PB1 chromosomes, the system comprising:
- (i) means for performing a nucleic acid detection assay to interrogate at least 25 biallelic SNPs flanking the centromeres of said one or more PB1 chromosomes, said SNPs located within 5 to 10 Mb of the centromere;
- and
- (ii) a programmed storage device or medium comprising instructions assessing the presence or degree of centromeric heterozygosity (CH) for said one or more PB1 chromosomes, based on the results of the nucleic acid detection assay.
Dependencies are inferred from the claim text.